Najat Khan, CEO and President at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 23,588 shares at $3.58 ($84K) on 2026-06-05, disclosed to the SEC on 2026-06-05.
Scheduled sale ($84k) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RXRX | SELL | 2025-12-29 | $1.1M | — | Filing → |
| RXRX | SELL | 2025-08-19 | $404K | — | Filing → |